Cancer Genome Study Using Samples From Patients With Stage I or Stage II Non-Small Cell Lung Cancer Treated on Clinical Trial ACOSOG-Z0030

Alliance for Clinical Trials in Oncology70 enrolled

Overview

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030.

OBJECTIVES: * To investigate the clinical relevance of conducting comprehensive molecular analyses on clinically annotated high-quality tumor biospecimens from patients with stage I or II, N0 or N1 (less than hilar) non-small cell lung cancer. OUTLINE: This is a multicenter study. Biological specimens are collected from participating clinical sites and analyzed by transcription profiling of RNA and microRNA; detection of DNA copy number changes and chromosomal rearrangements; epigenetic modifications analyses; and sequencing of genomic segments, genes, and regulatory regions to assess sequence variation. Clinical information associated with each specimen donor is also collected.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lung Cancer

Interventions

DNA analysisGENETIC

RNA analysisGENETIC

microarray analysisGENETIC

mutation analysisGENETIC

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Diagnosis of non-small cell carcinoma * Primary, untreated disease * Stage I or II (T1 or T2, N0 or non-hilar N1, M0) disease * Any of the following histologies allowed: * Squamous cell carcinoma * Adenocarcinoma (\< 10%) * Large cell carcinoma (high-grade) * Available tumor tissue samples collected on clinical trial ACOSOG-Z0030 and meeting the following criteria: * Snap-frozen and stored at a temperature of -80°C or lower * Specimens may come from any site within the lung or one that is involved by direct regional extension of tumor from the originating site in the lung * No regional lymph node or distant metastases * No recurrent or persistent disease after prior neoadjuvant or adjuvant treatment for lung cancer * Must have matching frozen samples of normal tissue and blood

Outcomes

Primary Outcomes

Clinical relevance of conducting comprehensive molecular analyses on clinically annotated high-quality tumor biospecimens

Time frame: Up to 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.